Joseph Frattaroli
Plus aucun poste en cours
Fortune : 15 229 $ au 30/04/2024
Historique de carrière de Joseph Frattaroli
Anciens postes connus de Joseph Frattaroli
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Directeur Financier/CFO | 01/04/2018 | 31/03/2024 |
Vaso Active Pharmaceuticals, Inc.
 Vaso Active Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vaso Active Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The Company focuses on vaso active lipid encapsulated or VALE, transdermal delivery technology drugs. Currently, they market Athlete's Relief and Osteon in the United States. The Company's products, include Analgesics, Toenail fungal treatment, Acne, First aid, Hand and body lotion and Psoriasis treatment. It is planning to rebrand the deFEET athlete's foot anti-fungal medication product as Termin8 and Xtinguish. | Directeur Financier/CFO | 24/12/2009 | 06/11/2012 |
| President | 01/06/2003 | 06/11/2012 | |
| Flagship Consulting, Inc. | Fondateur | 01/01/2010 | - |
Formation de Joseph Frattaroli
| Salem State University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Director of Finance/CFO | 2 |
| President | 1 |
| Founder | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Vaso Active Pharmaceuticals, Inc.
Vaso Active Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vaso Active Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The Company focuses on vaso active lipid encapsulated or VALE, transdermal delivery technology drugs. Currently, they market Athlete's Relief and Osteon in the United States. The Company's products, include Analgesics, Toenail fungal treatment, Acne, First aid, Hand and body lotion and Psoriasis treatment. It is planning to rebrand the deFEET athlete's foot anti-fungal medication product as Termin8 and Xtinguish. | Health Technology |
| Flagship Consulting, Inc. |
- Bourse
- Insiders
- Joseph Frattaroli
- Expérience